Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
References
Chapter 1
. Ichikawa, M.,et al. 1991. A new multiple-unit oral floating dosage system. II: In vivo
evaluation of floating and sustained-release characteristics with p-aminobenzoic acid
and isosorbide dinitrate as model drugs. J. Pharm. Sci. 80, 1153–1156.
2. Kawashima, Y.et. al., 1991. Preparation of multiple unit hollow microspheres
(microballoons) with acrylicresin containing tranilast and their drug release
characteristics (in vitro) and floating behavior (in vivo). J. Control. Release 16, 279–
290.
3. Atyabi, F. et. al., 1996. In vivo evaluation of novel gastric retentive formulation based
on ion exchange resins. J. Control. Release 42, 105–113.
4. Iannuccelli, V. et. al.,1998. Air compartment multiple-unit system for prolonged
gastric residence. Part II. In vivo evaluation. Int. J. Pharm. 174, 55–62.
5. Hwang, S.J. et. al., 1998. Gastric retentive drug-delivery systems. Crit. Rev. Ther.
Drug Carrier Syst. 15, 243–284.
6. Moës, A.J., 1993. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst.
10, 143–195.
7. Deshpande, A. et. al., 1996. Controlled-release drug delivery systems for prolonged
gastric residence: overview. Drug Dev. Ind. Pharm. 22, 531–539.
8. Rouge, N. et. al., 1996. Drug absorption sites in gastrointestinal tract and dosage
forms for site-specific delivery. Int. J. Pharm. 136, 117–139.
9. Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: approach to oral
controlled drug delivery via gastric retention. J. Control. Release 63, 235–259.
10. Sheth, P.R., Tossounian, J.L., 1979a. Sustained release tablet formulations. U.S.
Patent 4,140,755.
11. Sheth, P.R., Tossounian, J.L., 1979b. Novel sustained release tablet formulations.
U.S. Patent 4,167,558.
12. Baumgartner, S. et. al., 2000. Optimisation of floating matrix tablets and evaluation
of their gastric residence time. Int. J. Pharm. 195, 125–135.
13. Colombo, P. et. al., 1989. The role of compression force in floating tablet formula
optimization. Acta Pharm. Technol. 35, 168–170.
14. Gerogiannis, V.S. et. al., 1993. Floating and swelling characteristics of various
excipients used in controlled release technology. Drug Dev. Ind. Pharm. 19, 1061–
1081.
15. Rouge, N. et. al., 1997. Screening of potentially floating excipients for minitablets.
STP Pharma Sci. 7, 386–392.
16. Baumgartner, S., Smid-Korbar, J.,Vrecer, F., Kristl, J., 1998. Physical and
technological parameters influencing floating properties of matrix tablets based on
cellulose ethers. STP Pharma Sci. 8, 285–290.
17. Ingani, H.M., Timmermans, J., Moës, A.J., 1987. Conception and in vivo
investigation of peroral sustained release floating dosage forms with enhanced
gastrointestinal transit. Int. J. Pharm. 35, 157–164.
18. Yang, L., Fassihi, R., 1996. Zero-order release kinetics from self- correcting floatable
asymmetric configuration drug delivery system. J. Pharm. Sci. 85, 170–173.
19. Yang, L., Eshraghi, J., Fassihi, R., 1999. A new intragastric delivery system for
treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation.
J. Control. Release 57, 215–222.
20. Timmermans, J., Moës, A.J., 1990. How well do floating dosage forms float? Int. J.
Pharm. 62, 207–216.
21. Müller,W., Anders, E., 1989. Floating system for oral therapy.WO Patent 89/06956.
22. Siepmann, J., Peppas, N.A., 2001. Modeling of drug release from delivery systems
based on hydroxypropyl methylcellulose. Adv. Drug Deliv. Rev. 48, 139–157.
23. Siepmann, J., Streubel, A., Peppas, N.A., 2002. Understanding and predicting drug
delivery from hydrophilic matrix tablets using ‘‘sequential layer’’ model. Pharm. Res.
19, 306–314.
24. Velasco, M.V., Ford, J.L., Rowe, P., Rajabi-Siahboomi, A.R., 1999. Influence of
drug: hydroxypropylmethylcellulose ratio, drug and polymer particle size and
compression force on release of diclofenac sodium from HPMC tablets. J.
Control. Release 57, 75–85.
25. Sung, K.C., Nixon, P.R., Skoug, J.W., Ju, T.R., Gao, P., Topp, E.M., Patel, M.V.,
1996. Effect of formulation variables on drug and polymer release from HPMC-based
matrix tablets. Int. J. Pharm. 142, 53–60.
26. Colombo, P., Conte, U., Gazzaniga, A., Maggi, L., Sangalli, M.E., Peppas, N.A., La
Manna, A., 1990. Drug release modulation by physical restrictions of matrix swelling.
Int. J. Pharm. 63, 43–48.
27. Conte, U., Maggi, L., Colombo, P., La Manna, A., 1993. Multi-layered hydrophilic
matrices as constant release devices (Geomatrix_ Systems). J. Control. Release 26,
39–47.
28. Desai S. A Novel Floating Controlled Release Drug Delivery System Based on Dried
Gel Matrix Metrix [master’s thesis]. [thesis]. Jamaica, NY: St John’s
University; 1984.
29. Vantrappen GR, Peeters TL, Janssens J. The secretory component of interdigestive
migratory motor complex in man. Scand J Gastroenterol. 1979; 14:663-667.
30. Wilson CG, Washington N. The stomach: its role in oral drug
delivery. In: Rubinstein MH, ed. Physiological Pharmacetical: Biological Barriers to
Drug Absorption. Chichester, UK: Ellis Horwood; 1989:47-70.
31. S Bolton, S Desai, Floating sustained release therapeutic compositions, US Patent,
4,814,179,March 21; 1989.
32. R C Mamajek, E S Moyer, Drug dispensing and method US patent 4,207,890, June
17; 1980 through C.A.1984 K50391.
33. L Whitehead, J T Fell J H Collett, Development of Gastroretentive Dosage Form.
European Journal of Pharmaceutical Sciences; 1996,4 (1): S182.
34. V Iannuccelli, G Coppi, R Sansone and G Ferolla, Aircompartment Multiple-unit
System for Prolonged GastricResidence, Part II. Invivo Evaluation.
InternationalJournal of Pharmaceutics; 1998,174 (1–2): 55–62.
35. N R Jimenez Castellanos, H Zia and C Rhodes, Mucoadhesive Drug Delivery
Systems. Drug Development and Industrial Pharmacy; 1993, 19: 143.
36. R Talukder and R Fissihi, Gastroretentive delivery systems: A mini review. Drug
Dev. Ind. Pharm.; 2004, 30 (10): 1019-1028.
37. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of novel controlled
release system for gastric retention. Pharm Res. 1997;14:815-819.
38. Burns SJ, Attwood D, Barnwell SG. Assesment of dissolution vessel designed for
use with floating and erodible dosage forms. Int. J. Pharm. 1998;160:213-218.
39. Joseph NJ, Laxmi S, Jayakrishnan A. A floating type oral dosage from for piroxicam
based on hollow microspheres: in vitro and in vivo evaluation in rabbits. J. Control
Release. 2002;79:71-79.
40. Sheth PR, Tossounian JL, inventors. Sustained release pharmaceutical capsules. US
patent 4,126,672. November 21, 1978.
41. Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. Microspheres as
floating drug delivery system to increase gastric residence of drugs. Drug Metab
Rev. 2001;33:149-160.
42. Ichikawa M, Watanabe S, Miyake Y. A new multiple unit oral floating dosage
system. I: Preparation and in vitro evaluation of floating and sustained-release
kinetics. J. Pharm. Sci. 1991;80:1062-1066.
43. Ichikawa M, Watanabe S, Miyake Y, inventors. Granule remaining in stomach. US
patent 4 844 905. July 4, 1989.
44. Ozdemir N, Ordu S, Ozkan Y. Studies of floating dosage forms of furosemide: in
vitro and in vivo evaluation of bilayer tablet formulation. Drug Dev. Ind.
Pharm. 2000;26:857-866.
45. Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for floating
drug delivery: effects of CO2 gas forming agents. Int. J. Pharm. 2002;239:81-91.
46. Li S, Lin S, Daggy BP, Mirchandani HL, Chien TW. Effect of formulation variables
on floating properties of gastric floating drug delivery system. Drug Dev. Ind.
Pharm. 2002;28:783-793.
47. Li S, Lin S, Chien TW, Daggy BP, Mirchandani HL. Statistical optimization of
gastric floating system for oral controlled delivery of calcium. AAPS
PharmSciTech. 2001;2:E1.
48. Penners G, Lustig K, Jorg PVG, inventors. Expandable pharmaceutical forms. US
patent 5 651 985. July 29, 1997.
49. Fassihi R, Yang L, inventors. Controlled release drug delivery systems. US patent 5
783 212. July 21, 1998.
50. Talwar N, Sen H, Staniforth JN, inventors. Orally administered controlled drug
delivery system providing temporal and spatial control. US patent 6 261
601. July 17, 2001.
51. Michaels AS, Bashwa JD, Zaffaroni A, inventors. Integrated device for administering
beneficial drug at programmed rate. US patent 3 901 232. August 26, 1975.
52. Michaels AS, inventor. Drug delivery device with self actuated mechanism for
retaining device in selected area. US patent 3 786 813. January 22, 1974.
53. Moursy NM, Afifi NN, Ghorab DM, El-Saharty Y. Formulation and evaluation of
sustained release floating capsules of Nicardipine HCl. Pharmazie. 2003;58:38-43.
54. Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained release drug delivery
systems using polycarbonate microspheres capable of floating on gastric fluids. J.
Pharm. Pharmacol. 1993;45:21-24.
55. Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and release
kinetics. Drug Dev. Ind. Pharm. 2000;26:965-969.
56. Bulgarelli E, Forni F, Bernabei MT. Effect of matrix composition and process
conditions on casein gelatin beads floating properties. Int. J. Pharm. 2000;198:157-
165.
57. Whitehead L, Collett JH, Fell JT. Amoxycillin release from floating dosage form
based on alginates. Int. J. Pharm. 2000;210:45-49.
58. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density
foam powder: effect of formulation and processing parameters on drug release. Eur J
Pharm Sci. 2003;18:37-45.
59. Asmussen B, Cremer K, Hoffmann HR, Ludwig K, Roreger M, inventors. Expandable
gastroretentive therapeutic system with controlled active substance release in
gastrointestinal tract. US patent 6 290 989. September 18, 2001.
60. El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and evaluation of
ketoprofen floating oral drug delivery system. Int J Pharm. 2001;220:13-21.
61. Illum L, Ping H, inventors. Gastroretentive controlled release microspheres for improved
drug delivery. US patent 6 207 197. March 27, 2001.
62. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density
foam powder. Int. J. Pharm. 2002;241:279-292.
63. Ushomaru K, Nakachimi K, Saito H, inventors. Pharmaceutical preparations and
method of manufacturing them. US patent 4 702 918. October 27, 1987.
64. Dennis A, Timminis P, Lel K, inventors. Buoyant controlled release powder
formulation. US patent 5 169 638. December 8, 1992.
65. Spickett RGW, Vidal JLF, Escoi JC, inventors. Antacid preparation having prolonged
gastric residence. US patent 5,288,506. February 22, 1993.
66. Franz MR, Oth MP, inventors. Sustained release, bilayer buoyant dosage form. US
patent 5 232 704. August 3, 1993.
67. Wu W, Zhou Q, Zhang HB, Ma GD, Fu CD. Studies on nimodipine sustained release
tablet capable of floating on gastric fluids with prolonged gastric resident time. Yao
Xue Xue Bao. 1997;32:786-790.
68. Wong PSL, Dong LC, Edgren DE, Theeuwes F, inventors. Prolonged release active
agent dosage form adapted for gastric retention. US patent 6 120
803. September 19, 2000.
69. Mitra SB, inventor. Sustained release oral medicinal delivery device. US patent 4 451
260. May 29, 1984.
70. Harrigan BM, inventor. Drug delivery device for preventing contact of undissolved
drug with stomach lining. US patent 4 055 178. October 25, 1977.
71. Garima Chawla, Piyush Gupta, Vishal Koradia and Arvind K Bansal, Gastroretention:
A means to address regional variability in intestinal drug absorption. Pharmaceutical
technology; 2003,27(2):50-68.
72. Hetal N Kikani, A Thesis on, Floating drug delivery system, The North Gujarat
University, Patan; 2000-2001: 11-12.
73. Garg S, Sharma S. Gastroretentive drug delivery systems. Business Briefing:
Pharmatech 2003 Web Site. 5th edition. May 2003 Available at:
http://www.touchbriefings.com/cdps/cditem.cfm?NID=17&CID=5. Accessed
October 6, 2005.
74. S Sangekar, Evaluation of effect of food and specific gravity of tablets on gastric
retention time. Int. J. Pharm.; 1990,35(3): 34-53.
75. Xu WL, Tu XD, Lu ZD, Development of Gentamycin sulfate sustained-release tablets
remaining-floating in stomach.; 1991, 26(7): 541-545.
76. Mojaverian P, Ferguson RK, Vlasses PH, et al. Estimation of gastric residence time
of Heidelberg capsules in humans: effect of varying food
composition. Gastroenterology. 1985;89:392-397.
77. P Mojaverian, P H Vlasses, P E Kellner and M L Rocci, Effects of gender, posture,
and age on gastric residence time of indigestible solid: pharmaceutical considerations.
Pharm. Res.; 1998, 10:639–64.
78. N K Jain, Progress in controlled and novel drug delivery systems, First Ed.;
2004,CBS Publishers and Distributors, New Delhi, Bangalore: 84-85.
79. Timmermans J, Andre JM. Factors controlling buoyancy and gastric retention
capabilities of floating matrix capsules: new data for reconsidering controversy. J.
Pharm Sci. 1994;83:18-24.
80. Timmermans J, Gansbeke VB, Moes AJ. Assessing by gamma scintigraphy in vivo
buoyancy of dosage forms having known size and floating force profiles as function
of time. Vol I. Paris, France: APGI; 1989. 42-51.
81. J Timmermans and A J Moes, Measuring resulting weight of immersed tests material
II: Examnples of kinetic determination applied for monolithic dosage forms.
Acta.Pharma.Technol.; 1990,36(1):176-180.
82. Babu VBM, Khar RK. In vitro and In vivo studies of sustained release floating
dosage forms containing salbutamol sulphate. Pharmazie. 1990;45:268-270.
83. H G Shivkumar, D Vishakante Gwdaand T M Pramod Kumar, Floating controlled
drug delivery systems for prolong gastric residence. Indian J. Pharm. Edu.; 2004, 38
(4): 172-179.
84. Fell J T, Whitehead L, Collet H, Prolonged gastric retention using floating dosage
forms. Pharm Technology.; 2000,24(3): 82-90.
85. Hilton AK, Deasy PB, In vitro and in vivo evaluation of oral sustained-release
floating dosage form of amoxicillin trihydrate. Int J Pharm.; 1992,86(10): 79-88.
86. A J Moës, Gastric Retention Systems for Oral Drug Delivery. Business Briefing,
Drug Delivery Oral, Pharmtech; 2003:158-159.
1. James E F Reynolds: Martindale, The extra Pharmacopoeia, Thirty-First edition,
Royal Pharmaceutical Society, London; 1996: 901 - 902.
2. The United States Pharmacopoeia 26 /The National Formulary 21, Ranitidine
Hydrochloride, United States Pharmacopeial Convention, Inc,: 1615 – 1619.
3. Monograph<R, Clarke's Analysis of Drugs and Poisons,
http://www.medicinescomplete.com/mc/clarke/2006/
4. Ranitidine, http://www.drugs.com
5. Goodman & Gilman’s The pharmacological basis of therapeutics. Eleventh
edition. Brunton Laurence L., Lazo John S., Parker Keith L:Mc Graw Hill
Medical publication divison; 971-972, 1866.
6. Zantac Product information, GlaxoWellcome Inc.
7. Histamine H2 antagonists. In: Drug Facts and Comparisons. Fifty Sixth edition. St
Louis, MO: Wolters Kluwer Co; 2002:1192-1197.
8. British Pharmacopoeia 2005, Ranitidine, The Stationery Office on behalf of
Medicines and Healthcare products Regulatory Agency (MHRA): 1714 – 1716.
9. Indian Pharmacopoeia 1996, Ranitidine hydrochloride, The Controller of
Publications, Delhi © Govt. of India Ministry of Health and Family Welfare: 659-
661.
1. Raymond, C.R., 2003. Handbook of Pharmaceutical Excipients; American
Pharmaceutical association ,4th Edition,462-468
2. www.pharma-polymers.com
3. www.roehm.com
4. www.pformulate.com
5. www.corel Pharm chem.com
6. Vyas, S.P., Khar,R.K., 2002. Targeted and controlled drug delivery: novel carrier
systems ; CBS publication 1sr edition;417-430
7. Soppimath, K.S., Kulkarni, A.R., Rudzinski, W.E., 2001. Microspheres as floating
drug delivery system to increase gastric residence of drugs. Drug Metab Rev.
33,149-160.
8. Lee, J.H., Park, T.G., Choi, H.K., 1999. Development of oral drug delivery system
using floating microspheres. J Microencapsul. 16, 715-729.
9. KIM, B. K., Park, H. J., 2002. Preparation and evaluation of microspheres with
acrylic polymers by oil-in-oil emulsion solvent evaporation method: Annual
Meeting and Food Expo Anaheim, California.
10. Streubel, A., Siepmann, J., 2003. Multiple unit gastroretentive drug delivery
systems: new preparation method for low density microparticles. J Microencapsul.
20, 329-347.
11. Mathiowitz, E., 1999. Encyclopedia of controlled drug delivery, vol-1, New York:
John Wiley, 9-11.
12. Whitehead, L., Fell, J.T., Sharma, H.L., 1998. In vivo study demonstrating
prolonged gastric retention. J. Control Rel. 55,3-12.
13. Singh, B.N., Kim, K.H., 2000. Floating Drug Delivery Systems: An Approach to
Oral Controlled Drug Delivery via Gastric Retention. J. Control Rel. 63, 235-259.
14. Machida, Y., Inouye, K., 1989. Preparation and Evaluation of Intra gastric Buoyant
Preparations. Drug Des. Del. 4,155–161.
15. Gruber, P., 1987. Gastric Emptying of Non digestible Solids in Fasted Dog. J.
Pharm. Sci. 76, 117–122.
16. Sheth, P.R., Tossounian, J., 1984. The Hydro-dynamically Balanced System: A
Novel Drug Delivery System for Oral Use. Drug Dev. Ind. Pharm.10, 313–339.
17. Watanabe, S., 1976. Solid Therapeutic Preparation Remaining in Stomach. US
Patent 3 976 764. 24 August.
18. Michaels,A.S., Bashwa, J.D., 1975. Integrated Device for Administering Bene
ficialDrug at Programmed Rate. US Patent 3 901 232. 26 August.
19. Chang, H.S., 1985. Bioadhesive Polymers as Platforms for Oral Controlled Drug
Delivery II: Synthesis and Evaluation of Some Swelling, Water-Insoluble
Bioadhesive Polymers. J. Pharm. Sci. 74, 399–405
20. Davis, D.W., 1968. Method of Swallowing Pill. US Patent 3 418 999. 31 December.
21. Ichikawa, M., Watanabe, S., Miyake, Y., 1991. A New Multiple Unit Oral Floating
Dosage Systems, I: Preparation and In Vitro Evaluation of Floating and Sustained
Release Characteristics. J. Pharm. Sci. 80, 1062–1066
22. Mitra, S.B., 1984, Sustained Release Oral Medicinal Delivery Device. US Patent 4
451 260. 29 May.
23. Kawashima, Y., 1992. Hollow Microspheres for Use as Floating Controlled Drug
Delivery System in Stomach. J. Pharm. Sci.81, 135–140.
24. Fell, J.T., Whitehead, L., Collett, J.H., 2000. Prolonged Gastric Retention Using
Floating Dosage Forms Pharm. Technol. 82–90.
25. Iannuccelli, V., 1998. Air Compartment Multiple-Unit Systems for Prolonged
Gastric Residence Part I: Formulation Study. Int. J. Pharm. 174, 47–54.
26. Sakr, F.M., 1999. A Programmable Drug Delivery System for Oral Administration.
Int. J. Pharm. 184, 131–139.
27. Michaels, A.S., 1974. Drug Delivery Device with Self-Actuated Mechanism for
Retaining Device in Selected Area. US Patent 3 786 813. 22 January.
28. Michaels, A.S., Bashwa, J.D., Zaffaroni, A., 1975. Integrated Device for
Administering Beneficial Drug at Programmed Rate. US Patent 3 901 232. 26
August.
29. Hilton, A.K., Deasy, P.B., 1992. In Vitro and In Vivo Evaluation of Oral Sustained-
Release Floating Dosage Form of Amoxycillin Trihydrate. Int. J. Pharm. 86, 79–88.
30. Sheth, P.R., Tossounian, J.L., 1979. Novel Sustained Release Tablet
Formulations.US Patent 4 167 558
31. Sheth, P.R., Tossounian, J., 1984. The Hydrodynamically Balanced System: A
Novel Drug Delivery System for Oral Use. Drug Dev. Ind.Pharm. 10, 313–339.
32. Gupta, P.K., Robinson, J.R., 1992. Oral Controlled Release Delivery in Treatise on
Controlled Drug Delivery, A. Kydonieus, Eds. Marcel Dekker, New Jersey, 255–
310.
33. Seng, C.H., 1985. Bioadhesive Polymers as Platforms for Oral Controlled Drug
Delivery II—Synthesis and Evaluation of Some Swelling, Water-Insoluble
Bioadhesive Polymers. J. Pharm. Sci. 74, 399–405.
34. Park, K., Robinson, J.R., 1984. Bioadhesive Polymers as Platforms for Oral
Controlled Drug Delivery: Method to Study Bioadhesion. Int. J. Pharm. 19, 107–
127.
35. Chien, Y.W., 1992. Oral Drug Delivery Systems, in Novel Drug Delivery Systems,
Marcel Dekker, New York, 139–196.
36. Lehr, C.M., Hass, J., 2002. Developments in Area of Bioadhesive Drug Delivery
Systems. Expert Opinion on Biological Therapy 2, 287–298.
37. Caldwell, L.J., Gardner, C.R., Cargill, R.C., 1988. Drug Delivery Device Which
Can Be Retained in Stomach for Controlled Period of Time. US Patent 4 735 804. 5
April.
38. Gupta, P., Vermani, K., Garg, S., 2002. Hydrogels: From Controlled Release to pH-
Responsive Drug Delivery. Drug Discov. Today 7, 569–579.
39. Deshpande, A.A., 1997. Development of Novel Controlled-Release System for
Gastric Retention Pharm. Res. 14, 815–819.
40. Devereux, J.E., Newton, J.M., Short, M.B., 1990. The Influence of Density on
Gastrointestinal Transit of Pellets. J. Pharm. Pharmacol. 42, 500–501
41. Clarke, G.M., Newton, J.M., Short, M.B., 1995. Comparative Gastrointestinal
Transit of Pellet Systems of Varying Density. Int. J. Pharm.114, 1–11.
42. Thanoo, A.C., Sunny, M.C., Jaykrishnan, A., 1993. Oral sustained release drug
delivery systems using polycarbonate microspheres capable of floating on gastric
fluid. J. Pharm. Pharmacol. 45, 21-24.
43. Talukder, R., 2004. Gastroretentiver delivery systems: mini review drug dev. Ind.
Pharm.,30, 1019-1028.
44. Baumgartner, S., Kristel, J., Vreer, F., 2000. Optimisation of floating matrix tablets
and evaluation of their gastric residence time. Int. J. Pharm. 195, 125-135.
45. Sheth, P.R., Tossounian, J., 1984. The hydrodynamically balanced systems (HBS):
novel drug delivery system for oral use. Drug Dev Ind. Pharm.10, 313-339.
46. Menon, A., Ritschel, W.A., Sakr, A., 1994. Development and evaluation of
monolithic floating dosage form for furosemide. J Pharm Sci. 83, 239-245.
47. Phuapradit, W., Bolton, S., 1991. Influence of tablet density on oral absorption of
sustained release acetaminophen matrix tablets. Drug Dev Ind Pharm. 17, 1097-
1107.
48. Kedzierewicz, F., Thouvenot, P., Lemut, J., Etienne, A., 1999. Evaluation of peroral
silicone dosage forms in humans by gammascintigraphy. J. Control Release. 58,
195-205.
49. Groning, R., Heun, G., 1984. Oral dosage forms with controlled gastrointestinal
transit. Drug Dev Ind Pharm.10,527-539.
50. Groning, R., Heun, G., 1989. Dosage forms with controlled gastrointestinal passage
studies on absorption of nitrofurantion. Int J Pharm. 56, 111-116.
51. Ichikawa, M., Watanabe, S., Miyake, Y., 1991. A new multiple-unit oral floating
dosage system. II: In vivo evaluation of floating and sustained-release
characteristics with para amino benzoic acid and isosorbide dinitrate as model
drugs. J. Pharm. Sci. 80, 1153-1156.
52. Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: approach to oral
controlled drug delivery via gastric retention. J Control Release 63, 235-259.
53. Timmermans, J., Andre, J,M., 1994. Factors controlling buoyancy and gastric
retention capabilities of floating matrix capsules: new data for reconsidering
controversy. J. Pharm. Sci. 83, 18-24.
54. Garg, S., Sharma, S., 2003. Gastroretentive drug delivery systems. Business
Briefing Pharmatech.
55. Joseph, N.J., Laxmi, S., Jayakrishnan, A., 2002. A floating type oral dosage from
for piroxicam based on hollow microspheres: in vitro and in vivo evaluation in
rabbits. J. Control Release.79, 71-79.
56. Dennis, A., Timminis, P., Lel, K., 1992. Buoyant controlled release powder
formulation. US patent 5 169 638. 8 December.
57. Burns, S.J., Attwood, D., Barnwell, S.G., 1998. Assesment of dissolution vessel
designed for use with floating and erodible dosage forms. Int J Pharm. 160, 213-
218.
58. Yang, L., Esharghi, J., Fassihi, R., 1999. A new intra gastric delivery system for
treatment of helicobacter pylori associated gastric ulcers: in vitro evaluation. J
Control Release. 57, 215-222.
59. Gibaly, E.I., 2002. Development and evaluation of novel floating chitosan
microcapsules: comparision with non floating chitosan microspheres. Int J
Pharm.249, 39-47.
60. Sato, Y., Kawashima, Y., 2003. In vitro and in vivo evaluation of riboflavin
containing microballoons for floating controlled drug delivery system in healthy
human volunteers. J Control Release. 93, 39-47.
61. Shimpi, S., Chauhan, B., Mahadik, K.R., Paradkar, A., 2004. Preparation and
evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by
melt granulation. AAPS Pharm Sci Tech 5, E43.
62. Dave, B.S., Amin, A.F., Patel, M.M., 2004. Gastroretentive drug delivery system of
ranitidine hydrochloride: formulation and in vitro evaluation. AAPS Pharm Sci
Tech. 5, E34.
63. Sriamornsak, P., Thirawong, N., Puttipipatkhachorn, S., 2004. Morphology and
buoyancy of oil entrapped calcium pectinate gel beads. AAPS Pharm Sci Tech 6,
E24.
64. Shweta, A., Ali, J., Khar, R.K., 2005. Floating Drug Delivery Systems: A Review.
AAPS Pharm SciTech. 6, E372-E790.
65. Illum, L., Ping, H., 2001. Gastroretentive controlled release microspheres for
improved drug delivery. US patent 6 207 197. 27March.
66. www. drugs.com
Chapter 2
Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: approach to oral controlled drug
delivery via gastric retention. J. Control. Release 63, 235–259.
2. Dave BS, Amin AF, Patel MM. 2004. Gastroretentive Drug Delivery System of Ranitidine
Hydrochloride: Formulation and In Vitro Evaluation. AAPS Pharm Sci Tech., 5(2), article
34.
3. Soppimath KS, Kulkarni AR, Rudzinski WE, Aminabhavi TM. 2001. Microspheres as
floating drug-delivery systems to increase gastric retention of drugs. Drug Metab Rev., 33(2),
149-160.
4. Baumgartner S, Krsti J, Zorko B, 2000. Optimisation of floating matrix tabletand evaluation
of gastric recidence time. Int. J. Pharm., 195(1), 125-135.
5. Shimpi S, Chauhan B, Mahadik K R, Paradkar P, 2004. Preparation and Evaluation of
Diltiazem Hydrochloride-Gelucire 43/01 Floating Granules Prepared by Melt Granulation.
AAPS Pharm Sci Tech., 5(3), 19-25.
6. Stockwell A F, Davis S S, Walker S E, In vitro evaluation of alginate gel systems as sustained
release drug delivery systems. J.Control.Release; 1986, 3: 167-175.
7. Igani H M, Timmermans J, Moes A J, 1987. Conception and in vitro investigation of peroral
sustained release dosage forms with enhanced gastrointestinal transit. Int. J. Pharm., 35, 157-
164.
8. Sheth P R, Tossounian J L, Sustained release pharmaceutical capsules, US patent,
4,126,672,November 21; 1978.
9. Sangejkar W, A Vadino, I Chaudary, A Parr, R Beihn, G Digenis, 1987. Evaluation of effect
of food and specific gravity of tablets on gastric retention time. Int. J. Pharm., 35, 187-191.
10. Nakamichi K, Yasuura H, Fukui H, Oka M, Izumi S, 2001. Evaluation of floating dosage
form of Nicardipine Hydrochloride and Hydroxy propyl methyl cellulose acetate succinate
prepared using twin-screw extruder. Int. J. Pharm., May 7, 218(1-2), 103-112.
11. Fabregas J L, Claramunt J, Cucala J, Pous R, Siles A, 1994. In vitro testing of antcid
formulation with prolong gastric residence time (Amalgate Flot-Coat), Drug. Dev. Ind.
Pharm., 20, 1199-1212.
12. Mazer N, Abisch E, Glffeler J C, Laplanche R, Bauer-frind P, Cucala M, Lukachick M, Blum
A, 1988. Intra gastric gastrointestinal behavior and absorption kinetic of normal and floating
modified release capsule of Iseradipine under fasted and fed conditions. J. Pharm. Sci., 89,
647-657.
13. Inouye K, Machida Y, Sanna T, Nagai T, 1988, Buoyant sustained release tablets based on
chitosan. Drugs Des. Del., 2, 165-175.
14. Kawashima Y, Niwa T, Tekeuchi H, Hino T, Itoh Y, 1992. Hollow microspheres for use as
floating controlled drug delivery system in stomach. J. Pharm. Sci., 81, 135-140.
15. Franz M R, Oth M P, Sustained release bilayer buoyant dosage form, US patent, 5,232,704,
August 3; 1993.
16. Desai S, Bolton S, 1993. A floating controlled drug delivery systems: In vitro in vivo
evaluation. Pharm. Res., 10, 1321-1325.
17. Du Quing, Fan Chum Sun, 1996. Preparation and evaluation of floating granules of
Aminophyllin. Through Chemical Abstract, 125(3), 6745u.
18. Whitehead L, Collette H, 2000. Prolong Gastric retention using floating dosage form. Pharm.
Tech., 3, 82-90.
19. Nur AO, Zhang JS, 2000. Captopril floating /or bioadhesive tablet: Design and release
kinetic. Drug. Dev. Ind. Pharm., 26(9), 965-970.
20. Shoufeng L, 2001. Stastastical Optimization of gastric floating system for oral controlled
delivery of calcium. AAPS Pharm. Sci. Tech., 2(1), 1-10.
21. Farouk M, 1999. A programmable drug delivery system for oral administration. Int. J.
Pharm., 184, 131-139.
22. Talwar N, Sen H, Orally administered controlled drug delivery system providing temporal
and spatial control, WO Patent, 151198; 2000.
23. Joseph N J, Lakshmi S, Jayakrishnan.A A A, 2002. A floating-type oral dosage form for
Piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in
rabbits, J. Controlled Release, 79(1), 71-79.
24. Patel V, Amiji M, 1996. Preparation and characterization of freeze dried chitosan Poly
(ethylene oxide) hydrogel for site-specific antibiotic delivery in stomach, Pharm. Res., 13,
588-593.
25. Atyabi, F., Sharma, H.L., Mohammad, H.A.H., Fell, J.T., 1996. In vivo evaluation of novel
gastric retentive formulation based on ion exchange resins. J. Control. Release 42, 105–113.
26. Yang, L., Eshraghi, J., Fassihi, R., 1999. A new intragastric delivery system for treatment of
Helicobacter pylori associated gastric ulcer: in vitro evaluation. J. Control. Release 57, 215–
222.
27. Timmermans J, Gansbeke B Van, Moes A J, 1989. Assising by gama scintigraphy in vivo
buoyancy of dosage form developing known size and floating fource profiles as function of
preparation. Proc, 5th Int. Conf. Pharm. Technol, Vol. I, APGI, Paris, 42-51.
28. Sheth P R, Tossounian J, 1984. Hydrodynamically balanced system (HBS): A novel drug
delivery system for oral use. Drug. Dev. Ind. Pharm., (10), 313-339.
29. Zhenphing Wei, Zhanfeng Yu, 2001. Design and Evaluation of two-layer floating tablets for
gastric retention using cisapride as model drug. Drug. Dev. Ind. Pharm., 27(5), 469-474.
30. Soppimeth Kumeresh, Aminabhavi Tejraj, 2001. Development of hollow microspheres as
floating controlled release systems for cardiovascular drugs: Preparation and release
characteristics. Drug. Dev. Ind. Pharm., 27(6), 507-515.
31. Zia H, Chueth H R, Rhodes C T, 1999. Optimization of Sotalol floating and bioadhesive
extended release tablet formulation. Drug. Dev. Ind. Pharm., 21, 1725-1747.
32. Ichikawa M, Kato T, Kawahara M, Watanabe S, Kayano M, 1991. A new multiple unit oral
floating dosage system. II: In vivo evaluation of floating and sustained release characteristics
with P-amino benzoic acid and Isosorbide Dinitrate as model drugs. J. Pharm. Sci., 80, 1153-
1156
33. Srivastava A. K., Wadhwa Saurabh, Mishra B.205.Oral Sustained Delivery of Atenolol from
Floating Matrix Tablets – Formulation and In Vitro Evaluation. Drug. Dev. Ind. Pharm.,
31(4-5), 367-374
1. Coffin; Mark D.; Parr; Alan F. US Patent 5,407,687. Ranitidine solid dosage form, April
1995.
2. Chopra; Sham K.; Nangia; Avinash K.; Lee; David; Molloy; Thomas P. US Patent 5,342,627,
Controlled release device, Aug 1994.
3. Mody; Shri Shirish Bhagwanlal; Doshi; Madhukant Mansukhlal; Joshi; Milind Dattatraya US
Patent 5,853,756, Controlled release formulations of Ranitidine, Dec 1998.
4. Quirk; Christopher W.; Jackson; David A.; Cameron; James M. US Patent 5,456,918,
Ranitidine pharmaceutical compositions, Oct. 1995
5. Davis; Adrian Francis US Patent 5,656,652, Compositions containing histamine H2 receptor
antagonists at low dosage, Aug 1997.
6. Dave BS, Amin AF, Patel MM. 2004. Gastroretentive Drug Delivery System of Ranitidine
Hydrochloride: Formulation and In Vitro Evaluation. AAPS Pharm. Sci.. Tech., 5(2), article
34.
7. Basit Abdul W. and Lacey Larry L., 2001. Colonic metabolism of ranitidine: implications for
its delivery and absorption. Int. J. Pharm. Sci., 227(1-2), 157 – 165.
Streubel A., Siepmann J., Bodmeier R., 2002. Floating microparticles based on low density foam
powder, Int. J. Pharm., 241, 279–292.
2. Streubel A., Siepmann J., Bodmeier R., 2003. Floating matrix tablets based on low density
foam powder: effects of formulation and processing parameters on drug release, European
Journal of Pharmaceutical Sciences, 18, 37–45.
67. El-Kamel, A.H., Sokar, M.S., Naggar, V.F., 2001.Preparation and evaluation of ketoprofen
floating oral drug delivery system. Int. J. Pharm. 220, 13-21.
68. Streubel, A., Siepmann, J., Bodmeier, R., 2002. Floating microparticles based on low
density foam powder. Int J Pharm. 241, 279-292.
69. Kawashima, Y., Niwa, T., Takeuchi, H., Hino, T., Ito, Y., 1991. Preparation of multiple
unit hollow microspheres (microballoons) with acrylic resins containing tranilast and their
drug release characteristics (in vivo). J. Control Rel. 16, 279-290.
70. Sato, Y., Kawashima, Y., 2003. In vivo evaluation of riboflavin-containing microballoons
for floating controlled drug delivery system in healthy human volunteers. J. Control Rel.
93, 39-47.
71. Sato, Y., Kawashima, Y., Takeuchi H.,Yamamoto, H., 2004. In vitro evaluation of floating
and drug releasing behaviors of hollow microspheres (microballoons) prepared by
emulsion solvent diffusion method. Eur. J. Pharm. Biopharm. 57,235-243.
72. Sato, Y., Kawashima, Y., Takeuchi H., Yamamoto, H., 2003. Physicochemical properties
to determine buoyancy of hollow microspheres (microballoons) prepared by emulsion
solvent diffusion method Eur. J. Pharm. Biopharm. 55, 297-304.
73. Kawashima, Y., Takeuchi H., Yamamoto, H., 2004. Design of pH-sensitive microspheres
for colonic delivery of immunosuppressive drug Tacrolimus. Eur. J. Pharm.Biopharm. 58,
37-43.
74. Dashevsky, A., 2004. pH-independent release of basic drug from pellets coated with
extended release polymer dispersion Kollicoat® SR 30 D and enteric polymer dispersion
Kollicoat® MAE 30 DP. Eur. J. Pharm. Biopharm. 58,45-49.
75. Beck, R., 2004. Nanoparticle coated microparticles: preparation and characterization; J.
Microencap. 21, 499 – 512.
76. Kulkarni, A. R., Rudzinski W.E., Tejraj, M., 2001. Microspheres as floating drug delivery
systems to increase gastric retention of drugs. Drug Metabolism Reviews. 33, 149 – 160.
77. Lee, J.H., Park, T.G., Lee, Y.B., Shin, S.C., Choi, H.K., 2001. Effect of adding non-volatile
oil as core material for floating microspheres prepared by emulsion solvent diffusion
method. J. Microencap. 18, 65 – 75.
78. Kumaresh, S., 2001. Development of Hollow Microspheres as Floating Controlled-Release
Systems for Cardiovascular Drugs: Preparation and Release Characteristics. Drug Dev. Ind.
Pharm.27, 507 – 515.
79. Lee, J.H., 1999. Floating microspheres bearing acetohydroxamic acid for treatment of
Helicobacter pylori. J Microencap. 16, 715-729.
80. Lee, J.H., Park, T.G., Choi, H.K., 1999. Development of oral drug delivery system using
floating microspheres. J Microencap. 16, 650-667.
81. Joseph, N.J., Lakshmi, S., Jayakrishnan, A., 2002. A floating type oral dosage form for
piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in
rabbits. J. Control. Rel. 79, 71-79
82. Lai, W.C., Liu, X., Wan P., Heng, S., 2005. Liquid phase coating to produce controlled
release alginate microspheres. J. Microencap. 22, 891-896.
83. Jain, D., Panda, A.K., Majumdar D.K., 2005. Eudragit S100 Entrapped Insulin
Microspheres for Oral Delivery. AAPS Pharm SciTech. 6, Article 16.
84. Haznedar, S., Dortunc, B., 2004. Preparation and in vitro evaluation of Eudragit
microspheres containing acetazolamide. Int. J. Pharm. 269,131-140.
85. Obeidat, W. M., Price, J., 2005. Preparation and evaluation of Eudragit S 100 (methacrylic
acid copolymer) microspheres as pH sensitive release preparations for piroxicam and
theophylline using emulsion-solvent evaporation method. AAPS Annual Meeting and
Exposition.
86. Al-Kassas, R., 2004. Design and in vitro evaluation of gentamicin Eudragit microspheres
intended for intraocular administration. J. Microencap. 21, 71 – 81.
87. Pao, C.W., Huang Y. B.,Chang J.S., 2003. Design and evaluation of sustained release
microspheres of potassium chloride prepared by Eudragit®. Eur. J. Pharm. Sci. 19, 115-
122.
88. Patel, J.K., Patel, R.P., Amin, A.F., Patel, M.M., 2005. Formulation and Evaluation of
Mucoadhesive Glipizide Microspheres. AAPS Pharm Sci. Tech. 6, E49-E55.
89. Curatolo, 1995. Gastric retention system for controlled drug release. US Patent 5 443 843.
22 August.
90. Chowdary, K.P.R., Rao, Y.S., 2003. Design and In Vitro and In Vivo Evaluation of
Mucoadhesive Microcapsules of Glipizide for Oral Controlled Release: A Technical Note.
AAPS Pharm Sci. Tech. 4, Article 3.
91. Bhagwat, 2005. Once-a-day controlled release sulfonylurea formulation. US Patent 6 875
793. 5 April.
92. Garcia, J., Ghaly, E.S., 2001. Evaluation of bioadhesive glipizide spheres and compacts
from spheres prepared by extruder/marumerizer technique. Pharm Dev Technol. 6, 407-
417.
93. Chowdary, K.P.R., Malathi, K., 2004. Ethyl Cellulose Microspheres of Glipizide:
Characterization, In Vitro and In Vivo Evaluation. Indian J. Pharm. Sci. 66, 412-416.
94. Jamzad, S., Fassihi, R., 2006. Development of controlled release low dose class II drug-
Glipizide. Int. J. Pharm. 312, 24-32.
95. Kuczynski, 1996. Dosage form for administering oral hypoglycemic glipizide US Patent 5
545 413. 13 August.
96. Verma, R. K., Garg, S., 2005. Selection of excipients for extended release formulations of
glipizide through drug excipient compatibility testing. J. Pharm. Biomed. Ana. 38, 633-
644.
Chapter 4
1. Histamine H2 antagonists. In: Drug Facts and Comparisons. Fifty Sixth edition. St Louis,
MO: Wolters Kluwer Co; 2002:1192-1197.
2. Somade S, Singh K. Comparative evaluation of wet granulation and direct compression
methods for preparation of controlled release Ranitidine HCL tablets. Indian J Pharm Sci.
2002;64:285.
3. Lauritsen K. Clinical pharmacokinetics of drugs used in treatment of gastrointestinal diseases.
Clinical Pharmacokinetics. 1990;19:11-31, 94-125.
4. Grant S. Ranitidine: updated review of its pharmacodynamic and pharmacokinetic properties
and therapeutic use in peptic ulcer and other allied diseases. Drugs. 1989;37:801-870.
5. Basit Abdul W. and Lacey Larry L., Colonic metabolism of ranitidine: implications for its
delivery and absorption. Int. J. Pharm. Sci. 2001, 227(1-2), 157 – 165.
6. Coffin; Mark D.; Parr; Alan F. US Patent 5,407,687. Ranitidine solid dosage form, April
1995.
7. Singh, B.N., Kim, K.H., 2000. Floating drug delivery systems: approach to oral controlled
drug delivery via gastric retention. J. Control. Release 63, 235–259.
8. Chawla G, Bansal A. A means to address regional variability in intestinal drug absorption.
Pharm Tech. 2003;27:50-68.
9. The United States Pharmacopoeia 26 /The National Formulary 21, Ranitidine Hydrochloride,
United States Pharmacopeial Convention, Inc,: 1615 – 1619.
10. Cooper J, Gun C, Powder Flow and Compaction. Inc Carter SJ, Eds. Tutorial Pharmacy. New
Delhi, hidix CBS Publishers and Distributors; 1986:211-233.
11. Shah D, Shah Y, Ramprashad M, Development and Evaluation of Controlled release
Diltiazem hydrochloride microparticles using cross-linked poly (vinyl-alcohol). Drug Dev.
Ind. Pharm; 1997,23(6): 567-574.
12. Aulton ME, Wells TI, Pharmaceutics: The Science of Dosage Form Design. London,
England, Churchill Livingston; 1998:247.
13. Martin A, Micromeretics, In: Martin A, ed. Physical Pharmacy.Baltimores, MD: Lippincott
Williams and Wilkins; 2001:423-454.
14. K Raghuram Reddy, Srinivas Mutalik, Srinivas Reddy, Once-daily sustained release matrix
tablets of Nicorandil: Formulation and in vitro evaluation, AAPS PharmSciTech; 2003,4(4):
1-9.
15. Paulo Costa, Jose Manuel, Sousa Labao, Modeling and comparison of dissolution profiles.
Eur. J. Pharm. Sci; 2001,13: 123-133.
16. Dettmar; Peter William; Dickson; Paul Andrew; Hampson; Frank Chadwick; Jollife; Ian
Gordon; Peers; William; US Patent 6,306,789, Mucoadhesive granules of carbomer suitable
for oral administration of drugs, Oct 1999.
17. Sabinus I. Ofoefule, Sunday E. Okoli and Amarauche Chukwu, Mechanisms behind
sustained release matrix tablets prepared with poly(acrylic) acid polymers, Acta Pharm., 50
(2000), 229-238.
18. Siepmann, J., Streubel, A., Peppas, N.A., 2002. Understanding and predicting drug delivery
from hydrophilic matrix tablets using ‘‘sequential layer’’ model. Pharm. Res. 19, 306–314.
19. Vargas C.L, Ghaly E.S, Kinetic release of theophylline from hydrophilic swellable matrices,
Drug Dev. Ind. Pharm; 1999,25(9): 1045-1050.
20. Rosa M, Zia H, Rhodes T, Dosing and testing in-vitro of bioadhesive and floating drug
delivery system for oral application. Int. J. Pharm; 1994,105:65-70.
21. Baumgartner, S., Smid-Korbar, J.,Vrecer, F., Kristl, J., 1998. Physical and technological
parameters influencing floating properties of matrix tablets based on cellulose ethers. STP
Pharma Sci. 8, 285–290.
22. Timmermans, J., Moës, A.J., 1990. How well do floating dosage forms float? Int. J. Pharm.
62, 207–216.
23. Chatwal, G R., Anand S K., Instrumental Methods of Chemical Analysis (Analytical
chemistry). Fifth revised and Enlarged edition, Himalaya Publishing House: 2.29-2.82, 2005.
Chapter 5
1. Thanoo, B.C., Sunny, M.C., Jayakrishnan, A., 1993. Oral sustained release drug delivery
systems using polycarbonate microspheres capable of floating on gastric fluid. J. Pharm.
Pharmacol. 45, 21–24.
2. Stithit, S., Chen, W., Price, J.C., 1998. Development and characterization of buoyant
theophylline microspheres with near zero order release kinetics. J. Microencapsul. 15 ,
725– 730.
3. Lee, J.H., Park, T.G., Choi, H.K., 1999. Development of oral drug delivery system using
floating microspheres. J. Microencapsul. 16, 715– 729.
4. Whitehead, L., Fell, J.T., Collett, J.H., Sharma, H.L., Smith, A.M., 1998. Floating dosage
forms: in vivo study demonstrating prolonged gastric retention. J. Control. Rel. 55 ,3– 12.
5. Curatolo, 1995. Gastric retention system for controlled drug release. US Patent 5 443
843. 22 August.
6. Jain, S.K., Awasthi, A.M., Jain, N.K., Agrawal, G.P., 2005.Calcium silicate based
microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and in
vitro characterization. J. Control. Rel. 107, 300– 309.
7. Joseph, N.J., Lakshmi, S., Jayakrishnan, A., 2002. A floating-type oral dosage form for
piroxicam based on hollow polycarbonate microspheres: in vitro and in vivo evaluation in
rabbits. J. Control. Rel. 79, 71–79.
8. Cui, F., Gao, Y., Guan, Y., Yang, L., Zhang, L., Preparation of Roxithromycin-polymeric
microspheres by emulsion solvent diffusion method for taste masking. Int. J. Pharm.,
Accepted Manuscript.
9. Sato, Y., Kawashima, Y.H., Yamamoto, H., 2003. Physicochemical properties to
determine buoyancy of hollow microspheres (microballoons) prepared by emulsion
solvent diffusion method. Eur. J. Pharm. Biopharm. 55,297–304
10. US pharmacopeia 27, 2004.First Supplement. US Pharmacopeial Convention, Rockville,
MD, pp.867
11. Martin, A., Physical Pharmacy: Micromeritics. Philadelphia, PA: Lea & Febiger ; IVth ed
,1993, pp.431– 432.
Chapter 6
1. Sato, Y., Kawashima, Y., Takeuchi H.,Yamamoto, H., 2004. In vitro evaluation of
floating and drug releasing behaviors of hollow microspheres (microballoons) prepared
by emulsion solvent diffusion method. Eur. J. Pharm. Biopharm. 57,235-243.
2. Bhushan, B., 2006. Novel floating dosage form. US Patent Application, 20060013876, 19
January.
3. Jamzad, S., Fassihi, R., 2006. Role of Surfactant and pH on Dissolution Properties of
Fenofibrate and Glipizide: A Technical Note, AAPS Pharm Sci. Tech. 7 Article.2.
4. Patel, S., Patel, J., 2005. Studies in Design and development of chitosan microspheres
using different techniques. M. Pharm. Thesis. North Gujarat University.
5. US pharmacopeia 27, 2004.First Supplement. US Pharmacopeial Convention, Rockville,
MD, pp.867
6. Benet, L.Z., Oie, S., Schwartz, J.B., 1996. Design and optimization of dosage regimens,
pharmacokinetic data, In: Hardman, J.G., Limbird, L.E., Goodman and Gilman’s The
Pharmacological Basis of Therapeutics, Ninth ed., McGraw Hill, New York.
7. Verma, R.K., Garg, S., 2004. Development and evaluation of osmotically controlled oral
drug delivery system of glipizide. Eur. J. Pharm. Biopharm. 57, 513–525
8. Guidance for Industry SUPAC-MR. Modified Release Solid Oral Dosage Forms Scale-
Up and Postapproval Changes: Chemistry, Manufacturing, and Controls. In
vitroDissolution Testing and In Vivo Bioequivalence Documentation.
9. Moore, J., Flanner, H., 1996. Mathematical comparison of dissolution profiles. Pharm
Tech. 20, 64-74.
10. Soppimath, K., Kulkarni, A., Development of Hollow Microspheres as Floating
Controlled Release Systems for Cardiovascular Drugs, Preparation and Release
Characteristics, Drug Dev. Ind. Pharm. 27, 507 – 515.
11. Jain, S.K., Awasthi, A.M., Jain, N.K., 2005. Calcium silicate based microspheres of
repaglinide for gastroretentive floating drug delivery: Preparation and in vitro
characterization. J. Control. Rel. 107, 300– 309.
12. Costa, P., 2001. Modeling and comparision of dissolution profiles. Eur. J. Pharm. Sci.
13, 123-133.